APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer

Exclusion Criteria

• •1. Previous chemotherapy as primary treatment for locally advanced or metastatic pancreatic cancer(stage 3 T3 and T4, and all stage 4).
• •2. RT within 2 weeks or chemotherapy within 3 weeks or noncytotoxic investigational agents within 4 weeks of initiating study treatment.
• •3. Evidence of New York Heart Association class III or greater cardiac disease.
• •4. History of myocardial infarction, stroke, ventricular arrhythmia.
• •5. Symptomatic central nervous system metastases.
• •6. Pregnant or nursing women.
• •7. Hypersensitivity or intolerance to apricoxib, erlotinib, gemcitabine, sulfonamides, aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs).
• •8. History of upper gastrointestinal bleeding, ulceration or perforation. History of lower GI bleeding, ulceration, or perforation within 12 months.
• •9. Previous anti-EGFR kinase therapy.